http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 30 Jun 2026 06:00:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html <p>BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) announced positive topline results from its Phase 3 MANGROVE trial evaluating Brukinsa (zanubrutinib) plus rituximab against bendamustine plus rituximab in previously untreated mantle cell lymphoma (MCL) patients.</p> <p>The trial met its primary endpoint of progression-free survival (PFS), with the Brukinsa-based regimen reducing the risk of disease progression or death by 43% compared to standard chemoimmunotherapy (HR=0.57; 95% CI, 0.43, 0.76; p&lt;0.0001), as assessed by an independent review committee.</p> <p>The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab, http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html Tue, 30 Jun 2026 06:00:40 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html <p>BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) announced positive topline results from its Phase 3 MANGROVE trial evaluating Brukinsa (zanubrutinib) plus rituximab against bendamustine plus rituximab in previously untreated mantle cell lymphoma (MCL) patients.</p> <p>The trial met its primary endpoint of progression-free survival (PFS), with the Brukinsa-based regimen reducing the risk of disease progression or death by 43% compared to standard chemoimmunotherapy (HR=0.57; 95% CI, 0.43, 0.76; p&lt;0.0001), as assessed by an independent review committee.</p> <p>The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab, http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html Tue, 30 Jun 2026 06:00:40 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html <p>BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) announced positive topline results from its Phase 3 MANGROVE trial evaluating Brukinsa (zanubrutinib) plus rituximab against bendamustine plus rituximab in previously untreated mantle cell lymphoma (MCL) patients.</p> <p>The trial met its primary endpoint of progression-free survival (PFS), with the Brukinsa-based regimen reducing the risk of disease progression or death by 43% compared to standard chemoimmunotherapy (HR=0.57; 95% CI, 0.43, 0.76; p&lt;0.0001), as assessed by an independent review committee.</p> <p>The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab, http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html Tue, 30 Jun 2026 06:00:40 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html <p>BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) announced positive topline results from its Phase 3 MANGROVE trial evaluating Brukinsa (zanubrutinib) plus rituximab against bendamustine plus rituximab in previously untreated mantle cell lymphoma (MCL) patients.</p> <p>The trial met its primary endpoint of progression-free survival (PFS), with the Brukinsa-based regimen reducing the risk of disease progression or death by 43% compared to standard chemoimmunotherapy (HR=0.57; 95% CI, 0.43, 0.76; p&lt;0.0001), as assessed by an independent review committee.</p> <p>The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab, http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html Tue, 30 Jun 2026 06:00:40 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html <p>BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) announced positive topline results from its Phase 3 MANGROVE trial evaluating Brukinsa (zanubrutinib) plus rituximab against bendamustine plus rituximab in previously untreated mantle cell lymphoma (MCL) patients.</p> <p>The trial met its primary endpoint of progression-free survival (PFS), with the Brukinsa-based regimen reducing the risk of disease progression or death by 43% compared to standard chemoimmunotherapy (HR=0.57; 95% CI, 0.43, 0.76; p&lt;0.0001), as assessed by an independent review committee.</p> <p>The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab, http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html Tue, 30 Jun 2026 06:00:40 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html <p>BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) announced positive topline results from its Phase 3 MANGROVE trial evaluating Brukinsa (zanubrutinib) plus rituximab against bendamustine plus rituximab in previously untreated mantle cell lymphoma (MCL) patients.</p> <p>The trial met its primary endpoint of progression-free survival (PFS), with the Brukinsa-based regimen reducing the risk of disease progression or death by 43% compared to standard chemoimmunotherapy (HR=0.57; 95% CI, 0.43, 0.76; p&lt;0.0001), as assessed by an independent review committee.</p> <p>The MANGROVE study enrolled 510 patients across 176 sites worldwide. Patients in the experimental arm received Brukinsa at 160 mg orally twice daily plus rituximab, http://www.streetinsider.com/FDA/BeOne%27s+Brukinsa+cuts+lymphoma+progression+risk+by+43%25+in+trial/26708715.html Tue, 30 Jun 2026 06:00:40 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html <p class="bwalignc"> <i>Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p&lt;0.0001), meeting the primary endpoint of PFS</i> </p><p class="bwalignc"> <i>MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions</i> </p><p class="bwalignc"> <i>Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54562524&amp;newsitemid=20260630413578&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=5c3086da1360a160a8d4344809a7466e" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Announces+Positive+Phase+3+Results+for+BRUKINSA+in+Frontline+Mantle+Cell+Lymphoma/26708702.html Tue, 30 Jun 2026 06:00:00 -0400 06160 688235 A.60001765 O.20738543 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html <p class="bwalignc"> <i>Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment</i> </p><p class="bwalignc"> <i>BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54552031&amp;newsitemid=20260612883951&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=0e0eaf839010d7a5a3b17fa12947d048" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html Fri, 12 Jun 2026 06:00:00 -0400 06160 688235 A.06822034 A.31066700 O.20026344 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html <p class="bwalignc"> <i>Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment</i> </p><p class="bwalignc"> <i>BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54552031&amp;newsitemid=20260612883951&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=0e0eaf839010d7a5a3b17fa12947d048" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html Fri, 12 Jun 2026 06:00:00 -0400 06160 688235 A.06822034 A.31066700 O.20026344 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html <p class="bwalignc"> <i>Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment</i> </p><p class="bwalignc"> <i>BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54552031&amp;newsitemid=20260612883951&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=0e0eaf839010d7a5a3b17fa12947d048" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html Fri, 12 Jun 2026 06:00:00 -0400 06160 688235 A.06822034 A.31066700 O.20026344 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html <p class="bwalignc"> <i>Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment</i> </p><p class="bwalignc"> <i>BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54552031&amp;newsitemid=20260612883951&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=0e0eaf839010d7a5a3b17fa12947d048" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html Fri, 12 Jun 2026 06:00:00 -0400 06160 688235 A.06822034 A.31066700 O.20026344 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html <p class="bwalignc"> <i>Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment</i> </p><p class="bwalignc"> <i>BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54552031&amp;newsitemid=20260612883951&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=0e0eaf839010d7a5a3b17fa12947d048" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html Fri, 12 Jun 2026 06:00:00 -0400 06160 688235 A.06822034 A.31066700 O.20026344 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html <p class="bwalignc"> <i>Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment</i> </p><p class="bwalignc"> <i>BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54552031&amp;newsitemid=20260612883951&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=0e0eaf839010d7a5a3b17fa12947d048" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html Fri, 12 Jun 2026 06:00:00 -0400 06160 688235 A.06822034 A.31066700 O.20026344 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html <p class="bwalignc"> <i>Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment</i> </p><p class="bwalignc"> <i>BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54552031&amp;newsitemid=20260612883951&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=0e0eaf839010d7a5a3b17fa12947d048" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a http://www.streetinsider.com/Press+Releases/BeOne+Medicines%E2%80%99+Foundational+Hematology+Franchise+Leads+Next+Era+of+B-Cell+Cancer+Innovation+at+EHA+2026/26637712.html Fri, 12 Jun 2026 06:00:00 -0400 06160 688235 A.06822034 A.31066700 O.20026344 O.22422661 O.76306903 ONC